Shopping Cart
- Remove All
- Your shopping cart is currently empty
SDZ 224-015 is an orally active inhibitor of interleukin-1β (IL-1β) converting enzyme and caspase-1, exhibiting anti-COVID-19 and anti-inflammatory activity, and reducing carrageenan gum-induced paw edema in rats.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $149 | In Stock |
Description | SDZ 224-015 is an orally active inhibitor of interleukin-1β (IL-1β) converting enzyme and caspase-1, exhibiting anti-COVID-19 and anti-inflammatory activity, and reducing carrageenan gum-induced paw edema in rats. |
Targets&IC50 | IL-1β:0.24 µM |
In vitro | SDZ 224-015 dose-dependently inhibited the release of IL-1β from the human monocytic cell line THP-1, with an IC50 of 0.24 µM, without affecting the release of IL-6, TNF-α, or lactate dehydrogenase[2]. |
In vivo | SDZ 224-015 (0.3-300 micrograms kg-1) potently reduced carrageenin-induced paw oedema, with an oral ED50 of approximately 25 micrograms kg-1. SDZ 224-015 (0.2-5 mg kg-1, p.o.) displayed analgesic activity in the Randall-Selitto yeast-inflamed paw pressure test, significant at a dose of 1 mg kg-1, p.o[2]. |
Alias | SDZ 224015 |
Molecular Weight | 652.52 |
Formula | C30H35Cl2N3O9 |
Cas No. | 161511-45-1 |
Storage | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (122.60 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.